Helomics—acquired earlier this year by Precision Therapeutics—launched its new Precision Oncology Insights platform that provides a personalized oncology roadmap for oncologists and their patients. The platform will initially provide its recommendations for gynecologic cancers, with a focus on ovarian cancer. Precision Oncology Insights first tests living tumor tissue from a patient to determine how that patient’s tumor will respond to drugs. It then combines the drug response data with other genomic and molecular data. The results are then analyzed by its Helomics’ AI-enabled knowledgebase called D-CHIP (Dynamic Clinical Health Insights Platform), to generate a personalized treatment plan for each patient.